The stock price of Alx Oncology Holdings Inc (NASDAQ: ALXO) has dropped by -5.41 compared to previous close of 1.85. Despite this, the company has seen a gain of 12.18% in its stock price over the last five trading days. zacks.com reported 2025-01-07 that Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.
Is It Worth Investing in Alx Oncology Holdings Inc (NASDAQ: ALXO) Right Now?
The stock has a 36-month beta value of 0.97. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ALXO is 30.91M, and at present, short sellers hold a 27.16% of that float. On January 10, 2025, the average trading volume of ALXO was 993.85K shares.
ALXO’s Market Performance
ALXO stock saw an increase of 12.18% in the past week, with a monthly gain of 1.74% and a quarterly increase of 8.02%. The volatility ratio for the week is 10.65%, and the volatility levels for the last 30 days are 12.46% for Alx Oncology Holdings Inc (ALXO). The simple moving average for the last 20 days is 4.14% for ALXO’s stock, with a simple moving average of -69.71% for the last 200 days.
Analysts’ Opinion of ALXO
Many brokerage firms have already submitted their reports for ALXO stocks, with Jefferies repeating the rating for ALXO by listing it as a “Hold.” The predicted price for ALXO in the upcoming period, according to Jefferies is $2 based on the research report published on December 19, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $14, previously predicting the price at $10. The rating they have provided for ALXO stocks is “Hold” according to the report published on March 08th, 2024.
Jefferies gave a rating of “Buy” to ALXO, setting the target price at $18 in the report published on December 08th of the previous year.
ALXO Trading at 13.11% from the 50-Day Moving Average
After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.18% of loss for the given period.
Volatility was left at 12.46%, however, over the last 30 days, the volatility rate increased by 10.65%, as shares surge +14.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.37% upper at present.
During the last 5 trading sessions, ALXO rose by +15.46%, which changed the moving average for the period of 200-days by -84.63% in comparison to the 20-day moving average, which settled at $1.6831. In addition, Alx Oncology Holdings Inc saw 4.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALXO starting from Pinto Shelly, who sale 2,221 shares at the price of $1.80 back on Jan 06 ’25. After this action, Pinto Shelly now owns 87,902 shares of Alx Oncology Holdings Inc, valued at $3,998 using the latest closing price.
Pinto Shelly, the Interim CFO of Alx Oncology Holdings Inc, sale 1,426 shares at $1.58 during a trade that took place back on Dec 30 ’24, which means that Pinto Shelly is holding 90,123 shares at $2,253 based on the most recent closing price.
Stock Fundamentals for ALXO
Current profitability levels for the company are sitting at:
- -64.47 for the present operating margin
- 0.74 for the gross margin
The net margin for Alx Oncology Holdings Inc stands at -60.95. The total capital return value is set at -1.04. Equity return is now at value -98.94, with -74.50 for asset returns.
Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -13.17. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -93.11.
Currently, EBITDA for the company is -158.4 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 34.58. The receivables turnover for the company is 2.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.82.
Conclusion
To sum up, Alx Oncology Holdings Inc (ALXO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
